Can a simple vancomycin taper beat a pricey drug for recurrent c. diff?
NCT ID NCT07328971
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a gradual taper of vancomycin is as good as a 10-day course of fidaxomicin at preventing another C. difficile infection. About 500 adults with a first or second C. diff episode will be randomly assigned to one of the two treatments. The main goal is to see how many people have a repeat infection within 56 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vancomycin and fidaxomicin
- What this could lead to
- If successful, this could offer a cheaper, simpler way to prevent repeat C. difficile infections, reducing hospital visits and improving quality of life.
- What could go wrong
- This is a non-inferiority trial, so even if vancomycin works, it may not be better than the current standard. Results may not apply to all patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIA DIFFICILE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
McGill University Health Centre
RECRUITINGMontreal, Quebec, H4A0B1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.